Aurora Spine (TSXV:ASG) - Aandelenkoers, Nieuws & Analyse

ASG Overzicht aandelen

Aurora Spine Corporation, via haar dochteronderneming Aurora Spine, Inc., houdt zich bezig met de ontwikkeling en distributie van minimaal invasieve interspinale fusiesystemen en -apparaten in Canada.

Over het bedrijf

ASG fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

Risicoanalyse

De winst is de afgelopen 5 jaar met 8% per jaar gedaald

Heeft minder dan 1 jaar cash runway

Heeft geen betekenisvolle marktkapitalisatie ( CA$30M )

Volatiele aandelenkoers in de afgelopen 3 maanden

Aurora Spine Corporation Concurrenten

Nanalysis Scientific

TSXV:NSCI

CA$40.7m

NuGen Medical Devices

TSXV:NGMD

CA$20.7m

Conavi Medical

TSXV:CNVI

CA$51.1m

MedX Health

TSXV:MDX

CA$16.2m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Aurora Spine
Historische aandelenkoersen
Huidige aandelenkoers	CA$0.39
52 Week Hoogtepunt	CA$0.47
52 Week Laag	CA$0.22
Bèta	0.63
11 maand verandering	39.29%
3 maanden verandering	39.29%
1 Jaar Verandering	-2.50%
33 jaar verandering	20.00%
5 jaar verandering	6.85%
Verandering sinds IPO	-71.11%

Recent nieuws en updates

Recent updates

Aurora Spine Corporation (CVE:ASG) Soars 26% But It's A Story Of Risk Vs Reward

Oct 19

We Think Aurora Spine (CVE:ASG) Has A Fair Chunk Of Debt

Oct 16

Aurora Spine Corporation's (CVE:ASG) Subdued P/S Might Signal An Opportunity

Aug 14

We Think Shareholders May Want To Consider A Review Of Aurora Spine Corporation's (CVE:ASG) CEO Compensation Package

Jun 19

Is Aurora Spine (CVE:ASG) A Risky Investment?

May 29

There Is A Reason Aurora Spine Corporation's (CVE:ASG) Price Is Undemanding

Mar 19

Would Aurora Spine (CVE:ASG) Be Better Off With Less Debt?

Oct 15

Why Investors Shouldn't Be Surprised By Aurora Spine Corporation's (CVE:ASG) Low P/S

Aug 11

Here's Why Aurora Spine (CVE:ASG) Can Afford Some Debt

May 01

Aurora Spine (CVE:ASG) Is Making Moderate Use Of Debt

Dec 22

Would Aurora Spine (CVE:ASG) Be Better Off With Less Debt?

Aug 23

Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?

May 04

Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?

Dec 23

Aurora Spine (CVE:ASG) Is Making Moderate Use Of Debt

Jun 11

A Look At The Intrinsic Value Of Aurora Spine Corporation (CVE:ASG)

Feb 26

Is Aurora Spine (CVE:ASG) A Risky Investment?

Nov 19

Rendement voor aandeelhouders

	ASG	CA Medical Equipment	CA Markt
7D	-16.1%	-2.7%	-1.1%
1Y	-2.5%	-6.5%	20.8%

Rendement versus industrie: ASG overtrof de Canadian Medical Equipment industrie, die het afgelopen jaar een rendement -6.5 % opleverde.

Rendement versus markt: ASG presteerde slechter dan Canadian Market, dat het afgelopen jaar een rendement van 20.8 % opleverde.

Prijsvolatiliteit

Is ASG's price volatile compared to industry and market?
ASG volatility
ASG Average Weekly Movement	14.7%
Medical Equipment Industry Average Movement	13.4%
Market Average Movement	8.3%
10% most volatile stocks in CA Market	17.5%
10% least volatile stocks in CA Market	2.9%

Stabiele aandelenkoers: De aandelenkoers van ASG is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 15% ) van ASG is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen Canadian.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2013	n/a	Trent Northcutt	www.aurora-spine.com

Aurora Spine Corporation, via haar dochteronderneming Aurora Spine, Inc, houdt zich bezig met de ontwikkeling en distributie van minimaal invasieve interspinale fusiesystemen en -apparaten in Canada. Het bedrijf biedt lumbale fusieapparaten voor het processus interspinos, zoals de ZIP, ZIP ULTRA, ZIP LP en ZIP-51 voor patiënten die lijden aan degeneratieve discusziekten; en interbody kooien met een Ti-coating van polyetheretherketon, die ruimte en stabiliteit bieden tussen de wervels terwijl het bot groeit om het fusieproces te voltooien. Het bedrijf levert ook steriel verpakte spinale infusie-implantaten met een coating van titaniumplasmaspray voor botgroei, evenals interbody-producten zoals EOS, VOX, Echo, Echo SD en EchoXL voor het lumbale deel van de wervelkolom en discovery voor cervicale procedures.

Aurora Spine Corporation Samenvatting

Hoe verhouden de winst en inkomsten van Aurora Spine zich tot de beurswaarde?
ASG fundamentele statistieken
Marktkapitalisatie	CA$30.19m
Inkomsten(TTM)	-CA$886.94k
Inkomsten(TTM)	CA$23.59m

1.3x

P/S-verhouding

-34.0x

Koers/Winstverhouding

Is ASG overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ASG resultatenrekening (TTM)
Inkomsten	US$16.90m
Kosten van inkomsten	US$6.70m
Brutowinst	US$10.21m
Overige uitgaven	US$10.84m
Inkomsten	-US$635.51k

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.0082
Brutomarge	60.39%
Nettowinstmarge	-3.76%
Schuld/Eigen Vermogen Verhouding	53.1%

Hoe presteerde ASG op de lange termijn?

Bekijk historische prestaties en vergelijking

ASG Overzicht aandelen

Beloningen

Risicoanalyse

Aurora Spine Corporation Concurrenten

TSXV:NSCI

CA$40.7m

TSXV:NGMD

CA$20.7m

TSXV:CNVI

CA$51.1m

TSXV:MDX

CA$16.2m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Third quarter 2024 earnings released

Aurora Spine Corporation (CVE:ASG) Soars 26% But It's A Story Of Risk Vs Reward

We Think Aurora Spine (CVE:ASG) Has A Fair Chunk Of Debt

Aurora Spine Corporation Announces Release of Its Hydra Osteo Onyx Lumbar System

Second quarter 2024 earnings released: US$0.023 loss per share (vs US$0.007 loss in 2Q 2023)

Aurora Spine Corporation's (CVE:ASG) Subdued P/S Might Signal An Opportunity

Recent updates

Third quarter 2024 earnings released

Aurora Spine Corporation (CVE:ASG) Soars 26% But It's A Story Of Risk Vs Reward

We Think Aurora Spine (CVE:ASG) Has A Fair Chunk Of Debt

Aurora Spine Corporation Announces Release of Its Hydra Osteo Onyx Lumbar System

Second quarter 2024 earnings released: US$0.023 loss per share (vs US$0.007 loss in 2Q 2023)

Aurora Spine Corporation's (CVE:ASG) Subdued P/S Might Signal An Opportunity

We Think Shareholders May Want To Consider A Review Of Aurora Spine Corporation's (CVE:ASG) CEO Compensation Package

Is Aurora Spine (CVE:ASG) A Risky Investment?

Full year 2023 earnings released: US$0.02 loss per share (vs US$0.022 loss in FY 2022)

Aurora Spine Corporation to Report Q1, 2024 Results on May 13, 2024

Aurora Spine Corporation, Annual General Meeting, Jun 26, 2024

New minor risk - Insider selling

Independent Director recently sold CA$135k worth of stock

There Is A Reason Aurora Spine Corporation's (CVE:ASG) Price Is Undemanding

New minor risk - Share price stability

Aurora Spine Corporation to Showcase Sacroiliac Joint (Si Joint) Fusion Products At North American Neuromodulation Society Annual Meeting

Aurora Spine Corporation Announces Newly Published Paper on First 6-Month Clinical Evaluation of its ZIP™? Fusion Implant

Third quarter 2023 earnings released: US$0.004 loss per share (vs US$0.002 loss in 3Q 2022)

Independent Director recently bought CA$105k worth of stock

Aurora Spine Corporation announced that it has received CAD 1.933782 million in funding

Would Aurora Spine (CVE:ASG) Be Better Off With Less Debt?

Aurora Spine Corporation Announces Full Release of its SiLO TFX™? MIS Sacroiliac Joint Fixation System

Second quarter 2023 earnings released: US$0.01 loss per share (vs US$0.002 loss in 2Q 2022)

Why Investors Shouldn't Be Surprised By Aurora Spine Corporation's (CVE:ASG) Low P/S

Aurora Spine Corporation Announces Initial Patient Enrolled for DEXA-CTM Multicenter Study

Aurora Spine Corporation to Report Q1, 2023 Results on May 24, 2023

Aurora Spine Corporation, Annual General Meeting, Jun 28, 2023

Here's Why Aurora Spine (CVE:ASG) Can Afford Some Debt

Full year 2022 earnings released: US$0.02 loss per share (vs US$0.04 loss in FY 2021)

Independent Chairman exercised options to buy CA$355k worth of stock.

Aurora Spine (CVE:ASG) Is Making Moderate Use Of Debt

Third quarter 2022 earnings released: US$0.002 loss per share (vs US$0.007 loss in 3Q 2021)

Aurora Spine Corporation to Report Q3, 2022 Results on Nov 21, 2022

Insufficient new directors

Aurora Spine Corporation Announces Positive Interim Results from Clinical Study Using Zip(TM) MIS Interspinous Fusion System

Aurora Spine Corporation Announces FDA 510(K) Clearance for Its Silo TFX MIS Sacroiliac Joint Fixation System

Second quarter 2022 earnings released: US$0.002 loss per share (vs US$0.013 loss in 2Q 2021)

Aurora Spine Corporation to Report Q2, 2022 Results on Aug 29, 2022

Would Aurora Spine (CVE:ASG) Be Better Off With Less Debt?

Aurora Spine Announces New FDA Indication Clearance of Lumbar Spinal Stenosis for Its ZIP™ Series of MIS Implants

Aurora Spine Corporation Receives FDA 510(K) Clearance for Its Dexa Solo-LTM Spinal Fusion System

Aurora Spine Corporation to Report Q1, 2022 Results on May 23, 2022

Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?

Full year 2021 earnings released: US$0.04 loss per share (vs US$0.004 loss in FY 2020)

Insufficient new directors

Aurora Spine Corporation Announces Initial Implantation of the First Bone Density Matched DEXA-C Cervical Interbody Fusion Device

Aurora Spine Corporation Provides Revenue Guidance for Fourth Quarter and Full Year 2021

Aurora Spine Corporation Receives Notice of Allowance for Patent for Spinal Implant for Motion Preservation or Fusion

Aurora Spine Corporation Completes First Anterior Cervical Discectomy and Fusion Procedures with its Proprietary APOLLOTM Anterior Cervical Plate

Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?

Aurora Spine Corporation Announces Newly Published Paper on Need for A Bone Mineral Density-Matched Interbody Cage

Third quarter 2021 earnings released: US$0.02 loss per share (vs US$0.006 profit in 3Q 2020)

Aurora Spine Corporation Will Showcase Its New FDA-Cleared DEXA-C Anterior Fusion Cages At the North American Spine Society Annual Meeting

Aurora Spine Corporation announced that it has received CAD 6.508139 million in funding

Second quarter 2021 earnings released: US$0.01 loss per share (vs US$0.001 profit in 2Q 2020)

Aurora Spine Corporation Provides Revenue Guidance for the Year 2021

Aurora Spine Corporation Announces First Patients in Multicenter Study of ZIP® Interspinous Fixation Device

Aurora Spine Corporation Announces FDA 510(K) Clearance for DEXA-C Cervical Interbody System

Aurora Spine (CVE:ASG) Is Making Moderate Use Of Debt